Goldman Sachs Reiterates Buy Rating on Bristol-Myers Squibb Co. (BMY)
Tweet Send to a Friend
Goldman Sachs analyst Chris Shibutani reiterated a Buy rating and $57.00 price target on Bristol-Myers Squibb Co. (NYSE: BMY).The analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
